Related Experiment Video
Updated: Nov 26, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer
Xiaoyan Han1, Linlin Wang1, Ting Li1
1Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, China.
Abstract:
The emergence of immune checkpoint blockade to activate host T cells to attack tumor cells has revolutionized the cancer treatment landscape over the past decade. However, sustained response has only been achieved in a small proportion of patients. This can be attributed to physiological barriers, such as T-cell heterogeneity and immunosuppressive tumor microenvironments. To this can be added obstacles intrinsic to traditional antibody-driven blockade methods, including the inability to inhibit checkpoint translocation from cytoplasm, systemic immune toxicity, and "bite back" effect on T cells. Using non-small cell lung cancer (NSCLC) as the cancer model, here we report an unconventional, yet powerful, tumor-targeted checkpoint blocking strategy by RNAi nanoengineering for T-cell-independent cancer therapy. Unlike antibodies, such nanoblocker silences both membranous and cytoplasmic PD-L1 in cancer cells, thus eliminating the binding step. Moreover, it is demonstrated that silencing of PD-L1 by the nanoblocker can cause the direct programmed cell death of NSCLC H460 cells, without the need of T-cell intervention. In vivo results from xenograft tumor models further demonstrate that tumor-homing peptide modification enables the nanoblocker to accumulate in the tumor tissue, downregulate the PD-L1 expression, and inhibit the tumor growth more efficiently than the nontargeted group. These findings may offer an effective means toward overcoming barriers against traditional checkpoint blockade and provide different insights into the molecular mechanism(s) underlying immunotherapy.
Insights
A novel RNAi nanoblocker targets PD-L1 in cancer cells, offering a T-cell-independent immunotherapy approach. This strategy silences PD-L1, inducing cancer cell death and inhibiting tumor growth in non-small cell lung cancer models.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Immune checkpoint blockade revolutionized cancer therapy but shows limited response rates.
- Barriers include T-cell heterogeneity, immunosuppressive tumor microenvironments, and limitations of antibody-based blockade.
- Traditional methods struggle with cytoplasmic checkpoint translocation, systemic toxicity, and T-cell 'bite back' effects.
Purpose of the Study:
- To develop a novel, tumor-targeted checkpoint blocking strategy using RNAi nanoengineering.
- To investigate a T-cell-independent cancer therapy approach for non-small cell lung cancer (NSCLC).
- To overcome limitations of traditional antibody-driven immunotherapy.
Main Methods:
- Utilized RNAi nanoengineering to create a tumor-targeted nanoblocker.
- Applied the strategy to a non-small cell lung cancer (NSCLC) model.
- Investigated the nanoblocker's ability to silence both membranous and cytoplasmic PD-L1.
- Assessed T-cell-independent programmed cell death induction.
- Evaluated *in vivo* efficacy using xenograft tumor models with tumor-homing peptide modification.
Main Results:
- The nanoblocker effectively silenced both membranous and cytoplasmic PD-L1 in cancer cells.
- PD-L1 silencing by the nanoblocker induced direct programmed cell death of NSCLC cells, independent of T-cells.
- *In vivo* studies showed tumor-homing peptide modification enhanced nanoblocker accumulation, PD-L1 downregulation, and tumor growth inhibition.
- The targeted nanoblocker demonstrated superior efficacy compared to the non-targeted group.
Conclusions:
- RNAi nanoengineering offers a powerful, tumor-targeted strategy for checkpoint blockade.
- This T-cell-independent approach overcomes key limitations of traditional antibody-based immunotherapies.
- The findings provide new insights into immunotherapy mechanisms and potential treatments for NSCLC.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...